SCHEMBL30744282

SCHEMBL30744282

C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N(C)CC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.48
REN P00797 4/20 0.48
DPP4 P27487 3/20 0.47
FAP Q12884 2/20 0.47
DPP7 Q9UHL4 2/20 0.47
PREP P48147 1/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP9 Q86TI2 1/20 0.47
KDM4E B2RXH2 1/20 0.45
F2 P00734 1/20 0.45
LMNA P02545 1/20 0.45
LTA4H P09960 1/20 0.45
MAPT P10636 1/20 0.45
PEPD P12955 1/20 0.45
ALOX15 P16050 1/20 0.45
PTGS1 P23219 1/20 0.45
HTR2A P28223 1/20 0.45
PTGS2 P35354 1/20 0.45
HRH1 P35367 1/20 0.45
THPO P40225 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11274437 0.80 ACE (0.48) ACERENKDM4EF2LMNA
SCHEMBL11284810 0.78 ACE (0.46) ACERENKDM4EF2LMNA
SCHEMBL7271951 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL2115246 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL19824765 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL8316371 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL593691 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL9164453 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL2115244 0.78 ACE (0.64) ACERENDPP4FAPDPP7
SCHEMBL152403 0.78 ACE (0.64) ACERENDPP4FAPDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R ACE 621/4885REN 1815/4885DPP4 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.